Tandem Diabetes Care has positive artificial pancreas data

Data from a Tandem Diabetes Care (Nasdaq:TNDM) study demonstrated the benefits of its automated insulin delivery technology. […]

Data from a Tandem Diabetes Care (Nasdaq:TNDM) study demonstrated the benefits of its automated insulin delivery technology.

Diabetes Technology & Therapeutics made data available from the Control-IQ Observational (CLIO) study. It’s the largest prospective study of the Control-IQ advanced hybrid closed-loop technology to date. Twelve-month results showed, among other results, lower adverse events for type 1 diabetes patients using the technology.

Tandem Diabetes Care develops automated insulin delivery products, including its flagship t:slim X2 pump with Control-IQ technology. The company last month won FDA clearance for its Mobi automated insulin delivery system, which is less than half the size of the t:slim X2.

Control-IQ technology automatically observes and manages blood glucose levels. This artificial pancreas employs an insulin pump that uses sophisticated algorithms based on glucose monitoring data from the Dexcom G6 CGM, adjusting insulin dosage as required. The FDA has cleared Control-IQ for use in individuals aged 6 and older with type 1 diabetes.

Original article: (https://www.massdevice.com/tandem-diabetes-care-positive-artificial-pancreas-data/#:~:text=Data%20from%20a%20Tandem%20Diabetes,IQ%20Observational%20(CLIO)%20study.)